Celyad Oncology

Celyad Oncology's team wishes you a #merrychristmas and a happy #newyear 2025! 🎄 🎄

We’re excited to announce the release of the full agenda for #ATW25! 🚀 Join us in Dallas from Jan 20-23 for Advanced Therapies Week 2025, where over 2,200 therapeutic developers, pharma, VCs, and cell & gene therapy innovators will gather for knowledge sharing, deal-making, and collaboration. This year’s agenda features an incredible lineup, including visionary leaders like Eytan Breman (Celyad Oncology) and Nathan Moore, PhD (Takeda). Don’t miss the Women in Advanced Therapies Summit, Investment Summit, and our Superplenary—a few highlights of what’s to come! 🌟 Secure your place today! https://ow.ly/oAwJ50U4vb3 #AdvancedTherapies #BiotechInnovation #HealthcareTransformation #Phacilitate

#SITC2024 is now over. Our team had a great time attending high quality presentations, discussing with well renowned speakers and presenting posters! Should you be interested in our latest advances, you could find the presented posters here: https://lnkd.in/eZbgeDPV Eytan Breman, Matteo Rossi, Wout Frederickx

👨🔬 #BIOEuropeFall bat son plein à Stockholm. La Wallonie y est présente en force avec 50 entreprises belges du secteur des sciences de la vie. ⚗️ Parmi elles : Amyl Therapeutics et sa nouvelle approche des maladies neurodégénératives Artialis , spin off de l'Université de Liège spécialisée dans les troubles musculo-squelettiques Celyad Oncology spécialiste des traitements des cancers par thérapie cellulaire CER Groupe, centre de recherche spécialisé en virologie et hormonologie convEyXO qui traite la fibrose et les inflammations chroniques à partir d’exosomes DeuterOncology NV qui développe des médicaments ciblés contre le cancer comme le DO-2, un inhibiteur deutéré de la kinase MET Estetra, spécialiste de la santé des femmes avec un accent sur la contraception et la ménopause EuroscreenFast EXO Biologics qui utilise des exosomes pour traiter des maladies rares dont des maladies respiratoires, les maladies inflammatoires de l’intestin, la neurologie et l’oncologie.  EyeD Pharma qui développe des implants oculaires pour les patients souffrant de glaucome par exemple Hyloris Pharmaceuticals qui réinventer des médicaments à partir de molécules existantes IDDI - Regulatory Statistics & Clinical Data Science Experts, experte en science des données cliniques, fournit aux biotechs et entreprises pharma des services d'essais cliniques InhaTarget Therapeutics et son traitement innovant du cancer du poumon par inhalation Op2Lysis qui développe des médicaments pour lyser les hématomes et les caillots sanguins formés lors d’une thrombose dans le cerveau Le Réseau LiEU qui rassemble les connaissances de 6 Universités en Wallonie afin que les chercheurs et les partenaires privés et publics puissent stimuler les collaborations RLM Consulting qui apporte un soutien aux affaires réglementaires à toutes les étapes du développement du médicament Seqalis, spécialisée dans la fourniture de tests et de techniques de laboratoire de pointe et de haute qualité et les services de conseil scientifique et de recherche et développement, en pathologie anatomique, cytogénomique et biologie moléculaire Spectralys - Chauvin Arnoux Group, cette spin-off de l'Université libre de Bruxelles fournit des services d’analyses par spectroscopie FTIR pour les biomolécules Biotech Syngulon qui développe des bactériocines THERAtRAME qui utilise l'intelligence artificielle pour lutter contre le cancer UNIVERCELLS et ses technologies disruptives dans la production de biomolécules White Raven,  sous-traitant pharmaceutique (CDMO) actif dans la formulation et le remplissage aseptique de batch de produits injectables en faible volume 🎯 Emmené par Wallonia Export & Investment Agency et le pôle wallon de la santé, BioWin ce panel d'entreprises et d'acteurs de la recherche, illustre la richesse de l'écosystème de notre région en matière de #biotechnologie et d'innovation pharmaceutique 💊 #innovation #sciencesdelavie #santé #wallonie #investir #biotech Wallonia in Sweden

👨🔬 #BIOEuropeFall is in full swing in Stockholm. Wallonia is out in force with 50 Belgian companies from the life sciences sector. ⚗️ Among them: Amyl Therapeutics and its new approach to neurodegenerative diseases Artialis , a spin-off from the Université de Liège specialising in musculoskeletal disorders Celyad Oncology, a specialist in cancer treatment using cell therapy CER Groupe, a research centre specialising in virology and hormonology convEyXO, which uses exosomes to treat fibrosis and chronic inflammation DeuterOncology NV, which develops targeted cancer drugs such as DO-2, a deuterated MET kinase inhibitor Estetra, a specialist in women's health with a focus on contraception and the menopause EuroscreenFast EXO Biologics , which uses exosomes to treat rare diseases including respiratory diseases, inflammatory bowel diseases, neurology and oncology EyeD Pharma, which develops ocular implants for patients suffering from glaucoma, for example Hyloris Pharmaceuticals, which reinvents drugs from existing molecules IDDI - Regulatory Statistics & Clinical Data Science Experts, providing clinical trial services to biotech and pharma companies InhaTarget Therapeutics and its innovative inhaled treatment for lung cancer Op2Lysis, which is developing drugs to lyse haematomas and blood clots formed during thrombosis in the brain The Réseau LiEU Network, which brings together the knowledge of 6 universities in Wallonia so that researchers and private and public partners can stimulate collaborations RLM Consulting , which provides regulatory affairs support at all stages of drug development Seqalis, specialising in the supply of high-quality, state-of-the-art laboratory tests and techniques, scientific consultancy and R&D services in anatomical pathology, cytogenomics and molecular biology Spectralys - Chauvin Arnoux Group, this spin-off from the Université libre de Bruxelles provides FTIR spectroscopy analysis services for biomolecules Biotech Syngulon, which develops bacteriocins THERAtRAME, which uses artificial intelligence to fight cancer UNIVERCELLS and its disruptive technologies for the production of biomolecules White Raven, a pharmaceutical subcontractor (CDMO) active in the formulation and aseptic filling of low-volume batches of injectable products 🎯 Led by Wallonia Export & Investment Agency and the health cluster in Wallonia, BioWin, this panel of companies and research players illustrates the richness of our region's ecosystem in terms of #biotechnology and pharmaceutical innovation 💊 #innovation #lifesciences #health #wallonia #invest #biotech Wallonia in Sweden

⚗️ See you soon in Stockholm for #BIOEuropeFall, the major autumn event dedicated to healthcare biotechnologies and the pharmaceutical industry 💊 📆 From November 4 to 6, 2024 , Wallonia will be present with 50 Belgian companies from the life sciences sector. 🎯 Belgium is recognized as a hub for biotechnology and pharmaceutical innovation, with a strong #ecosystem that includes world-class #research institutions, cutting-edge #technology platforms and a collaborative environment that supports the growth 📈 of start-ups and established companies. 🤝 Join us at booth #96 to learn more about our region's assets and explore #partnership opportunities with our companies. 💡 As a reminder, Wallonia has set up an unprecedented technological innovation partnership in the field of #ATMPs (Advanced Therapy Medicinal Products). With over 20 years' experience in these new-generation biomedicines, the Walloon region intends to establish itself as a European leader in this field. 👉 More info: https://lnkd.in/dQebeUXe #innovation #lifesciences #health #wallonia #invest #biotech Wallonia Export & Investment Agency BioWin Wallonia in Sweden Amyl Therapeutics Artialis Celyad Oncology CER Groupe convEyXO DeuterOncology NV Estetra EuroscreenFast EXO Biologics EyeD Pharma Hyloris Pharmaceuticals IDDI - Regulatory Statistics & Clinical Data Science Experts InhaTarget Therapeutics Op2Lysis Réseau LiEU RLM Consulting Seqalis Spectralys Biotech Syngulon THERAtRAME Univercells SA White Raven

Congrats to our R&D scientist Marine Blackman for sharing our latest advances at the 2nd Annual MarketsandMarkets ImmunoBio Series conference!

We are eager to attend the 39th Annual Meeting of the Society for Immunotherapy of Cancer (#SITC2024), being held in Houston, November 6-10, 2024! If you’re attending too, don't forget to step by the posters presented by our scientists to learn more about our latest advances ! We will be presenting two posters: 👉 Abstract 262: PSMA/NKG2DL tandem CAR T-cells to overcome antigen heterogeneity and improve anti-tumor efficacy against prostate cancer, presented on Saturday, November 9. 👉 Abstract 1133: Efficient, safe and customizable modulation of multiple target genes in CAR T-cells through a miRNA-based shRNA platform, presented on Friday November 8. Eytan Breman, Wout Frederickx and Matteo Rossi will be happy to discuss with you and answer any question you might have!

Celyad Oncology a participé au 18ème Challenge Jogging-Marche Entreprise-Université Louvain-la-Neuve au profit de l'Association ELA (Association Européenne contre les Leucodystrophies). Félicitations à notre équipe pour la participation, une fois encore cette année!! 👏 Celyad Oncology took part to the 18th Challenge Jogging-Walking Entreprise-Université Louvain-la-Neuve in aid of the Association ELA (Association Européenne contre les Leucodystrophies). Congrats to our team for participating once again this year!!! 👏. #tousenbasketspourvaincrelamaladie #ela #fitatwork

Celyad Oncology announced the appointment of Matt Kane as its new Chief Executive Officer, effective October 1st. Matt Kane is a seasoned executive with over 20 years of experience in entrepreneurial, CEO and board roles. Mr. Kane is a pioneer in genome editing, led the development of the first editing technology to receive clearance for clinical evaluation as an in vivo gene insertion therapeutic and, most importantly, led the development and clinical testing of multiple allogeneic chimeric antigen receptor (CAR) T-cell therapies directed against cancer. Michel Lussier, co-founder of Celyad Oncology and Interim CEO, added: “Leading Celyad at our current stage of development requires a very unique set of skills: in-depth knowledge of the CAR T space, seasoned expertise in R&D out-licensing and IP monetization. We are very fortunate that Matt brings a solid track record in all these aspects.“ 👉 Read the full release: https://lnkd.in/e9D6NdjV